C-Further Launches First Pediatric Cancer Programs, Taps MiNK for PRAME iNKT Therapy

The consortium commits milestone-based, non-dilutive funding, including about $1.1 million to MiNK, to drive candidates to preclinical nomination.

Overview

CF-033 advances a PRAME-targeted, allogeneic iNKT cell therapy designed for off-the-shelf use without HLA matching or toxic lymphodepletion across multiple childhood cancers.
MiNK’s selection includes about $1.1 million in milestone-tied, non-dilutive support with potential double-digit downstream revenue participation under a non-exclusive collaboration.
University of Southampton investigators will run independent preclinical studies to evaluate activity, persistence and safety, with the goal of selecting a single lead candidate.
CF-012 brings together UVA, Dana-Farber and Mass General Brigham investigators to develop a small-molecule approach against ETV6 for the potential treatment of Ewing sarcoma.
An initial $40 million budget from core partners Cancer Research Horizons, LifeArc and Great Ormond Street Hospital Charity supports progression to preclinical candidate nomination subject to defined milestones.